pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PRMEPrime Medicine, Inc.

$PRME4.1900-1.87%
Cambridge, MA, USupdated 14h ago

Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Preclinical: 2Phase 2: 1
2Preclinical1Phase 2
Phase 2
PM-359
Chronic Granulomatous Disease
Preclinical
Glycogen Storage Disease 1B
Glycogen Storage Disease (GSD)
Preclinical
PM-577
Wilson Disease

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 6, 2026
earnings
$PRME4.1900-1.87%
11d ago
Prime Medicine, Inc. earnings
Prime Medicine, Inc.
→
view all catalysts →

Active trials

  • phase2A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)recruitingn=42
  • phase2A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )enrolling by invitationn=12
  • —Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trialrecruitingn=30
🐶 Hiring Signal
11 open roles at Prime Medicine, Inc. →

Where Prime Medicine, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 11
departmentManufacturing / CMC 2R&D / Discovery 2Regulatory 2IT & Engineering 1Medical Affairs 1

News

  • Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
    Former biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…
    biospace · 15d ago
  • FDA unveils guidance for ‘plug and play’ gene therapies
    The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.
    biopharma_dive · 19d ago
  • STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
    Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.
    stat · 3mo ago
identifiers
ticker
$PRME
SEC CIK
0001894562
country
US
source
sec_tickers
mentioned in
3news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 59m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?